We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant’s access program with Walgreens, which the company says will make the company’s products affordable, is slated to kick off this Friday with dermatology brands, according to Ari Kellen, executive vice president and company group chairman. Read More
The FDA continues to turn up the heat on compounding pharmacies, issuing two warning letters to compounders in Kentucky and California for serious GMP deficiencies related to sterility. Read More
With an eye toward patient-focused drug development, the FDA is seeking feedback on a compilation of clinical tools gathered together under a new pilot program. Read More
Biosimilar developers can expect the FDA to demand costly clinical trials to verify that a biosimilar is effectively identical with a reference product. Read More